# Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

> **NCT05185739** · PHASE2 · RECRUITING · sponsor: **University College, London** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab and Lenvatinib

## Key facts

- **NCT ID:** NCT05185739
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-25
- **Primary completion:** 2028-07
- **Final completion:** 2030-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05185739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05185739, "Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT05185739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*